Apresoline · DIN 00723754 · 20 mg/mL · injection solution-1mL vial
General benefitDormant since July 31, 2023 · checked November 19, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Apresoline · DIN 00723754
Manufacturer: Sterimax Inc.; listing date 1996-10-01
Health Canada: Dormant since 2023-07-31 · brand APRESOLINE · ATC C02DB02 HYDRALAZINE · form Solution · route Intravenous · ingredients HYDRALAZINE HYDROCHLORIDE 20 MG/ML · company Sterimax inc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00723754)
Source record
DIN 00723754: Apresoline
Raw flags: sec3=Y
Item: 240800044; group id 329; item number 0733; lccId None; manufacturer id STE
Source form: Inj Sol-1mL Vial Pk; strength: 20mg/mL
Recorded listing: General benefit
Source prices (unrounded): $11.6500; ministry $8.7375
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00723754
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12237
Interchangeable products
Hydralazine Hydrochloride Injection, USP · DIN 02516160 · $8.7375
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since July 31, 2023 — choose a marketed DIN from the same-category list.